Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis.

Publisher: BioMed Central Country of Publication: England NLM ID: 100968552 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2350 (Electronic) Linking ISSN: 14712350 NLM ISO Abbreviation: BMC Med Genet Subsets: MEDLINE

Original Publication: London : BioMed Central, [2000-

Biomarkers, Tumor/*metabolism ; Neoplasms/*metabolism ; Thrombospondin 1/*metabolism; Disease Progression ; Disease-Free Survival ; Humans ; Prognosis ; Proportional Hazards Models ; Publication Bias

Background: Published studies present conflicting data regarding the impact of Thrombospondin-1 (TSP-1) expression on prognosis of various cancers. We performed this meta-analysis to illustrate the preliminary predictive value of TSP-1.
Methods: Twenty-four studies with a total of 2379 patients were included. A comprehensive literature search was performed by using PubMed, Cochrane Library, Web of Science, Embase, and hand searches were also conducted of relevant bibliographies. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) for patient survival and disease recurrence were initially identified to explore relationships between TSP-1 expression and patient prognosis.
Results: A total of 24 eligible studies were included in this meta-analysis. Our results showed that high level of TSP-1 was correlated significantly with poor overall survival (OS) (HR = 1.40, 95% CI: 1.17 ~ 1.68; P<0.001). However, high TSP-1 expression predicted no significant impact on progression-free survival (PFS)/ metastasis-free survival (MFS) (HR = 1.35, 95%CI: 0.87-2.10; P = 0.176) and disease-free survival (DFS)/ recurrence-free survival (RFS) (HR = 1.40, 95%CI: 0.77-2.53; P = 0.271). In addition, we performed subgroup analyses which showed that high TSP-1 expression predicted poor prognosis in breast cancer and gynecological cancer. Additionally, the relatively small number of studies on PFS/MFS and DFS/RFS is a limitation. The data extracted through Kaplan-Meier curves may not be accurate. Moreover, only English articles were included in this article, which may lead to deviations in the results.
Conclusions: Our findings indicated high TSP-1 expression may act as a promising biomarker of poor prognosis in cancers, especially in breast cancer and gynecological cancer.

Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919)
Clin Cancer Res. 2002 May;8(5):1125-31. (PMID: 12006528)
Methods Enzymol. 1994;245:62-85. (PMID: 7539095)
Zhongguo Fei Ai Za Zhi. 2000 Jun 20;3(3):175-9. (PMID: 20950544)
Cold Spring Harb Perspect Biol. 2011 Oct 01;3(10):a009712. (PMID: 21875984)
Gynecol Oncol. 2009 Mar;112(3):583-9. (PMID: 19110305)
BMC Cancer. 2009 Aug 22;9:291. (PMID: 19698122)
Oncotarget. 2016 Feb 2;7(5):6105-20. (PMID: 26756218)
J Invest Dermatol. 2019 Jul;139(7):1497-1505.e5. (PMID: 30684555)
Clin Cancer Res. 2017 May 1;23(9):2335-2345. (PMID: 28151721)
Clin Cancer Res. 2005 Sep 15;11(18):6567-73. (PMID: 16166434)
Virchows Arch. 2001 Feb;438(2):116-20. (PMID: 11253112)
Cancer. 1998 Feb 15;82(4):632-8. (PMID: 9477093)
Biomol Ther (Seoul). 2017 Nov 1;25(6):625-633. (PMID: 28274095)
Cell Mol Life Sci. 2008 Mar;65(5):669-71. (PMID: 18193165)
J Hepatobiliary Pancreat Sci. 2016 Sep;23(9):565-73. (PMID: 27404020)
Int J Cancer. 2005 Sep 20;116(5):686-91. (PMID: 15838828)
Theranostics. 2019 Jul 9;9(17):4893-4908. (PMID: 31410189)
PLoS One. 2014 Apr 30;9(4):e96206. (PMID: 24788022)
Oncol Rep. 2012 Jan;27(1):216-24. (PMID: 22025320)
Cancer Res. 2011 Dec 15;71(24):7649-58. (PMID: 22037878)
Am J Pathol. 2001 Jul;159(1):223-35. (PMID: 11438469)
Gynecol Oncol. 2007 Jul;106(1):221-32. (PMID: 17481705)
Cell Oncol (Dordr). 2020 Feb;43(1):19-30. (PMID: 31485984)
Mol Pharmacol. 1999 Feb;55(2):332-8. (PMID: 9927626)
Am J Pathol. 1999 Aug;155(2):441-52. (PMID: 10433937)
BMC Cancer. 2016 Jul 15;16:483. (PMID: 27422280)
Int J Surg Pathol. 2002 Jan;10(1):47-56. (PMID: 11927969)
Liver Int. 2006 May;26(4):414-23. (PMID: 16629644)
Mol Biol Rep. 2013 Oct;40(10):5843-52. (PMID: 24057240)
Oncol Rep. 2001 Jul-Aug;8(4):763-6. (PMID: 11410779)
BMJ. 1997 Sep 13;315(7109):629-34. (PMID: 9310563)
Int J Cancer. 2001 Nov;94(4):508-12. (PMID: 11745436)
Mol Cell Proteomics. 2015 Nov;14(11):2936-46. (PMID: 26209610)
Int J Oral Maxillofac Surg. 2010 Jan;39(1):29-35. (PMID: 19906510)
Anticancer Res. 2015 Apr;35(4):2071-6. (PMID: 25862862)
Clin Cancer Res. 1999 Jan;5(1):155-61. (PMID: 9918214)
J Cell Mol Med. 2002 Jan-Mar;6(1):1-12. (PMID: 12003665)
Oncotarget. 2014 Jul 30;5(14):5782-97. (PMID: 25051363)
Anticancer Res. 2019 May;39(5):2317-2324. (PMID: 31092423)
Am J Physiol Renal Physiol. 2013 Jan 1;304(1):F19-30. (PMID: 23077100)
J Cell Biol. 1997 Aug 11;138(3):707-17. (PMID: 9245797)
Annu Rev Cell Dev Biol. 2001;17:25-51. (PMID: 11687483)
Int J Clin Oncol. 2011 Apr;16(2):145-52. (PMID: 21107877)
Int J Biochem Cell Biol. 2008;40(9):1890-900. (PMID: 18321763)
Oral Oncol. 2000 Nov;36(6):539-44. (PMID: 11036248)
J Natl Cancer Inst. 1997 Feb 5;89(3):219-27. (PMID: 9017002)
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4150-7. (PMID: 15217952)
Clin Cancer Res. 2001 Sep;7(9):2826-31. (PMID: 11555600)
Genes Dev. 2001 Jun 1;15(11):1373-82. (PMID: 11390357)

81672532 International National Natural Science Foundation of China; ZDRCA2016012 International Jiangsu Province's Key Provincial Talents Program; NO.BK20191077 International Natural Science Foundation of Jiangsu Province; KYCX18-1488 International Postgraduate Research & Practice Innovation Program of Jiangsu Province

Keywords: Malignant neoplasm; Meta-analysis; Overall survival; Prognosis; TSP-1

0 (Biomarkers, Tumor)
0 (Thrombospondin 1)

Date Created: 20200701 Date Completed: 20201028 Latest Revision: 20201028

20240105

PMC7325168

10.1186/s12881-020-01073-3

32600280